Your browser doesn't support javascript.
loading
Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina.
Palacios, Alfredo; Espinola, Natalia; Gonzalez, Juan Martin; Rojas-Roque, Carlos; Rivas, Maria Marta; Kanevski, Diego; Morisset, Pierre; Augustovski, Federico; Pichon-Riviere, Andres; Bardach, Ariel.
Afiliação
  • Palacios A; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
  • Espinola N; Department of Economics, Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Gonzalez JM; Centre for Health Economics (CHE), University of York, York, United Kingdom.
  • Rojas-Roque C; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
  • Rivas MM; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
  • Kanevski D; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
  • Morisset P; Centre for Health Economics (CHE), University of York, York, United Kingdom.
  • Augustovski F; Hospital Universitario Austral, Buenos Aires, Argentina.
  • Pichon-Riviere A; AbbVie Argentina, Buenos Aires, Argentina.
  • Bardach A; AbbVie Argentina, Buenos Aires, Argentina.
PLoS One ; 19(1): e0295798, 2024.
Article em En | MEDLINE | ID: mdl-38175833
ABSTRACT

OBJECTIVE:

This study aimed to estimate the budget impact of the incorporation of venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina.

METHODS:

A budget impact model was adapted to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax) for a third-party payer over a time horizon of three years. Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach. All direct medical costs were estimated by the micro-costing approach and were expressed in US dollars (USD) as of September 2020 (1 USD = 76.18 Argentine pesos).

RESULTS:

For a third-party payer with a cohort of 1,000,000 individuals covered, incorporating venetoclax was associated with an average budget impact per-member per-month (PMPM) of $0.11 USD for the social security sector and $0.07 USD for the private sector. The duration of treatment with venetoclax was the most influential parameter in the budget impact results.

CONCLUSION:

The introduction of venetoclax was associated with a positive and slight budget impact. These findings are informative to support policy decisions aimed to expand the current treatment landscape of AML.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: America do sul / Argentina Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Argentina País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: America do sul / Argentina Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Argentina País de publicação: Estados Unidos